Literature DB >> 402006

Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y.

W E Biddison, J C Palmer.   

Abstract

The immune reactivity to tumor cells within a progressively growing tumor mass in the syngeneic host has been analyzed by studying the cell-mediated cytolytic response of DBA/2 mice to the ascitic mastocytoma P815Y. Peritoneal cells from P815Y tumor-bearing hosts were fractionated by velocity sedimentation at unit gravity. Cell-mediated cytotoxicity of fractionated and unfractionated cells was measured by 51Cr-release from tumor target cells. The cell separation procedure revealed significant levels of specific cell-mediated cytotoxicity to P815Y within peritoneal cell populations at 8-16 days after tumor cell inoculation. Tumor cells purified from the peritoneal cell populations of mice injected with 10(3) tumor cells 10 days previously were as susceptible to syngeneic and allogeneic cell-mediated cytotoxicity as P815Y grown in vitro. However, tumor cells obtained from mice 16 days after tumor inoculation were resistant to cytolysis by syngeneic, but not allogeneic, effector cells. In addition, day 16 tumor cells did not inhibit syngeneic cell-mediated cytotoxicity against P815Y grown in vitro. Immunoglobulin was not detected on day 16 tumor cells and no circulating antibody to P815Y was found in the ascitic fluid of day 16 tumor-bearing mice. These results indicate that tumor cells may escape immune attack by loss of expression of cell surface tumor-associated antigens in the absence of circulating antibody against tumor.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 402006      PMCID: PMC393253          DOI: 10.1073/pnas.74.1.329

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  ANTIGENIC PROPERTIES OF EXPERIMENTAL LEUKEMIAS. I. SEROLOGICAL STUDIES IN VITRO WITH SPONTANEOUS AND RADIATION-INDUCED LEUKEMIAS.

Authors:  L J OLD; E A BOYSE
Journal:  J Natl Cancer Inst       Date:  1963-10       Impact factor: 13.506

Review 2.  Cell-mediated immunity to tumor cells.

Authors:  R B Herberman
Journal:  Adv Cancer Res       Date:  1974       Impact factor: 6.242

Review 3.  Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.

Authors:  K E Hellström; I Hellström
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

4.  Antigenic inhibition of cell-mediated cytotoxicity against tumour cells.

Authors:  G R Shellam; R A Knight
Journal:  Nature       Date:  1974-11-22       Impact factor: 49.962

5.  Serologic approaches to the study of cancer in animals and in man.

Authors:  L J Old; E A Boyse; G Geering; H F Oettgen
Journal:  Cancer Res       Date:  1968-07       Impact factor: 12.701

6.  Interaction of isoantibody and cytotoxic lymphocytes with allogeneic tumor cells.

Authors:  R B Faanes; Y S Choi
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

7.  Effect of antigen density on complement-mediated lysis, T-cell-mediated killing, and antigenic modulation.

Authors:  J Lesley; R Hyman; G Dennert
Journal:  J Natl Cancer Inst       Date:  1974-12       Impact factor: 13.506

Review 8.  Cell-mediated cytotoxicity, allograft rejection, and tumor immunity.

Authors:  J C Cerottini; K T Brunner
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

9.  Antigenic modulation in vitro. I. Fate of thymus-leukemia (TL) antigen-antibody complexes following modulation of TL antigenicity from the surfaces of mouse leukemia cells and thymocytes.

Authors:  C W Stackpole; J B Jacobson; M P Lardis
Journal:  J Exp Med       Date:  1974-10-01       Impact factor: 14.307

10.  Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus.

Authors:  H Kirchner; T M Chused; R B Herberman; H T Holden; D H Lavrin
Journal:  J Exp Med       Date:  1974-06-01       Impact factor: 14.307

View more
  10 in total

1.  Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma.

Authors:  R J North; E S Dye
Journal:  Immunology       Date:  1985-01       Impact factor: 7.397

2.  Antigenic variation in cancer metastasis: immune escape versus immune control.

Authors:  V Schirrmacher; M Fogel; E Russmann; K Bosslet; P Altevogt; L Beck
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

3.  Periodic loss of reactivity of a myeloma tumor with cytotoxic thymus-derived lymphocytes.

Authors:  J H Russell; A H Hale; L C Ginns; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

4.  Immunosuppressive tumor microenvironment in cervical cancer patients.

Authors:  Sytse J Piersma
Journal:  Cancer Microenviron       Date:  2011-05-31

5.  Variation of expression of histocompatibility antigens on tumor cells: absence of H-2Kk-gene products from a gross-virus-induced leukemia in BALB.K.

Authors:  W Schmidt; L Leben; G Atfield; H Festenstein
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

6.  The tumor dormant state. Comparison of L5178Y cells used to establish dormancy with those that emerge after its termination.

Authors:  K J Weinhold; D A Miller; E F Wheelock
Journal:  J Exp Med       Date:  1979-03-01       Impact factor: 14.307

7.  Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis.

Authors:  G Trinchieri; D Santoli
Journal:  J Exp Med       Date:  1978-05-01       Impact factor: 14.307

8.  Proliferative patterns of lymphocytes in lymph nodes during tumour development: involvement of T and B cell areas.

Authors:  M Bertschmann; R Markwalder-Hartenbach; E Pedrinis; M W Hess; H Cottier
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

9.  Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.

Authors:  C Uyttenhove; J Maryanski; T Boon
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

10.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.

Authors:  T Boon; J Van Snick; A Van Pel; C Uyttenhove; M Marchand
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.